BioNTech heads into May with earnings, shareholder vote and oncology pipeline focus

BioNTech enters a pivotal month with a shareholder vote on a major capital increase scheduled for May 15 and first-quarter earnings due on May 5. The company is navigating a transition from a pandemic-era powerhouse to a diversified oncology player as COVID-19 vaccine sales decline and spending on research, development and administration continues to climb.

In the last fiscal year, BioNTech generated revenue of roughly €2.87 billion but posted a net loss of €1.13 billion. Management has guided for lower sales in 2026, while the COVID-19 vaccine franchise, once a cash cow, is now a drag on the income statement.

The virtual annual general meeting on May 15 will ask shareholders to vote on a proposal to create new authorized capital that would allow the issuance of up to 129.5 million new shares, equivalent to half of the current share capital. The move is designed to give management the financial firepower to fund late-stage clinical trials and reduce the company's dependence on COVID-19 vaccine revenue. Alongside the capital resolution, the company plans to expand its supervisory board from six to eight members, adding two specialists in oncology and clinical development.

Away from the corporate calendar, the oncology pipeline is generating reasons for optimism. In mid-April, BioNTech and its partner DualityBio reported positive Phase 2 data for the antibody-drug conjugate candidate BNT323. In patients with advanced endometrial cancer, the study showed an objective response rate of approximately 49% and a median progression-free survival of 8.1 months.

The drug candidate, Trastuzumab Pamirtecan, also holds FDA Fast Track and Breakthrough Therapy designations. Phase 3 trials are underway, and a Biologics License Application is planned for 2026. The company is heavily investing in oncology, leveraging the same mRNA platform for personalized cancer therapies, and its 2025 R&D spend exceeded €1.5 billion.

The challenges in the legacy business remain acute. Comirnaty, developed in partnership with Pfizer, powered massive revenues during the pandemic but now contends with sharply declining demand. Pfizer and BioNTech recently halted a large U.S. study of their updated COVID-19 vaccine for adults aged 50 to 64 due to insufficient enrollment, making it impossible to generate data that would meet FDA standards.

In 2025, global COVID vaccine sales dropped over 50% year-over-year, hitting BioNTech's top line hard. FDA approvals keep the vaccine relevant for high-risk groups, yet routine vaccination hesitancy persists. The setback in the U.S. study comes just ahead of an expected May meeting of the FDA's advisory committee, which will influence strain selection for fall vaccines.

BioNTech's balance sheet remains supported by a large cash position, and cash reserves were described as still robust at over €17 billion post-pandemic. Strategic partnerships and ongoing investment in oncology infrastructure support the company's transformation, while investors will scrutinize on May 5 whether the oncology pipeline is already making a measurable contribution to revenue diversification or whether the COVID revenue gap still dominates the financial picture.